157 related articles for article (PubMed ID: 22849352)
1. Ipilimumab: a guide to its use in advanced melanoma.
Lyseng-Williamson KA; Sanford M
Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab: in previously treated patients with advanced melanoma.
Sanford M
BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
[TBL] [Abstract][Full Text] [Related]
4. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Hanaizi Z; van Zwieten-Boot B; Calvo G; Lopez AS; van Dartel M; Camarero J; Abadie E; Pignatti F
Eur J Cancer; 2012 Jan; 48(2):237-42. PubMed ID: 22030452
[TBL] [Abstract][Full Text] [Related]
5. Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Gonzalez R; Robert C; Schadendorf D; Hassel JC; Akerley W; van den Eertwegh AJ; Lutzky J; Lorigan P; Vaubel JM; Linette GP; Hogg D; Ottensmeier CH; Lebbé C; Peschel C; Quirt I; Clark JI; Wolchok JD; Weber JS; Tian J; Yellin MJ; Nichol GM; Hoos A; Urba WJ
N Engl J Med; 2010 Aug; 363(8):711-23. PubMed ID: 20525992
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab. Immunostimulant; more assessment needed.
Prescrire Int; 2012 Jun; 21(128):145-7. PubMed ID: 22822590
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
Libon F; Arrese JE; Rorive A; Nikkels AF
Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
[TBL] [Abstract][Full Text] [Related]
9. The ipilimumab lesson in melanoma: achieving long-term survival.
Delyon J; Maio M; Lebbé C
Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
McDermott D; Haanen J; Chen TT; Lorigan P; O'Day S;
Ann Oncol; 2013 Oct; 24(10):2694-2698. PubMed ID: 23942774
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
Eggermont AM
Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
[TBL] [Abstract][Full Text] [Related]
12. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
Robert C; Schadendorf D; Messina M; Hodi FS; O'Day S;
Clin Cancer Res; 2013 Apr; 19(8):2232-9. PubMed ID: 23444228
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in the treatment of melanoma.
Trinh VA; Hwu WJ
Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
17. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
18. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS;
Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564
[TBL] [Abstract][Full Text] [Related]
19. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
